Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
1. AVDL expands pipeline with valiloxybate for narcolepsy and idiopathic hypersomnia. 2. Initial studies for valiloxybate to start in Q4 2025; pivotal trial in 2026. 3. XWPharma receives $20 million upfront; potential for additional milestone payments. 4. Valiloxybate offers a salt-free, artificial sweetener-free dosing option. 5. LUMRYZ's success reinforces AVDL's leadership in sleep medicine therapies.